HC Wainwright Comments on Absci’s Q1 Earnings (NASDAQ:ABSI)

Absci Co. (NASDAQ:ABSI) – HC Wainwright decreased their Q1 2025 earnings per share estimates for Absci in a report released on Wednesday, March 19th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.27) per share for the quarter, down from their prior estimate of ($0.19). HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Absci’s current full-year earnings is ($0.89) per share. HC Wainwright also issued estimates for Absci’s Q2 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.83) EPS, FY2026 earnings at ($0.52) EPS, FY2027 earnings at ($0.31) EPS, FY2028 earnings at $0.20 EPS and FY2029 earnings at ($0.02) EPS.

Absci (NASDAQ:ABSI) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.03). Absci had a negative net margin of 2,321.56% and a negative return on equity of 46.56%. The business had revenue of $0.67 million during the quarter, compared to the consensus estimate of $1.77 million.

ABSI has been the topic of a number of other reports. Needham & Company LLC restated a “buy” rating and issued a $9.00 price target on shares of Absci in a research note on Wednesday. Guggenheim reissued a “buy” rating and issued a $10.00 price objective on shares of Absci in a research note on Thursday. Finally, KeyCorp decreased their target price on Absci from $6.00 to $5.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $8.57.

Absci Stock Performance

Shares of NASDAQ ABSI opened at $3.01 on Friday. Absci has a 52-week low of $2.45 and a 52-week high of $6.72. The company has a quick ratio of 5.63, a current ratio of 5.63 and a debt-to-equity ratio of 0.01. The firm’s 50-day moving average price is $3.86 and its 200-day moving average price is $3.66. The company has a market cap of $383.28 million, a PE ratio of -3.24 and a beta of 2.09.

Institutional Investors Weigh In On Absci

A number of hedge funds have recently bought and sold shares of the business. Two Sigma Advisers LP increased its position in shares of Absci by 191.9% during the 4th quarter. Two Sigma Advisers LP now owns 676,400 shares of the company’s stock valued at $1,772,000 after purchasing an additional 444,700 shares during the last quarter. Two Sigma Investments LP increased its position in Absci by 97.2% during the 4th quarter. Two Sigma Investments LP now owns 899,648 shares of the company’s stock valued at $2,357,000 after purchasing an additional 443,410 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Absci by 4.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 45,800 shares of the company’s stock valued at $120,000 after purchasing an additional 1,976 shares in the last quarter. Deutsche Bank AG increased its holdings in shares of Absci by 60.9% in the 4th quarter. Deutsche Bank AG now owns 74,170 shares of the company’s stock valued at $194,000 after acquiring an additional 28,073 shares during the period. Finally, Bank of America Corp DE grew its stake in Absci by 18.0% in the fourth quarter. Bank of America Corp DE now owns 88,197 shares of the company’s stock valued at $231,000 after purchasing an additional 13,476 shares during the last quarter. Hedge funds and other institutional investors own 52.05% of the company’s stock.

Absci Company Profile

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.